Humacyte
HUMA
147 hedge funds and large institutions have $53.1M invested in Humacyte in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 55 increasing their positions, 35 reducing their positions, and 15 closing their positions.
180% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $527K
57% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 35
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
4% more funds holding
Funds holding: 141 → 147 (+6)
0.69% more ownership
Funds ownership: 28.85% → 29.54% (+0.69%)
33% less capital invested
Capital invested by funds: $79.8M → $53.1M (-$26.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.1M |
| 2 |
BlackRock
New York
|
+$2.04M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.43M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.38M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$697K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$662K |
| 3 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$494K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$468K |
| 5 |
WA
Waverly Advisors
Birmingham,
Alabama
|
-$351K |
HUMA Hedge Fund Activity: Q4 2025 in Review
147 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q4 2025, worth a combined $53.1M — down 33% from $79.8M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new HUMA positions and 15 closed out — a net gain of 8 holders — while 55 added to existing stakes and 35 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.1M. The largest seller was Royal Bank of Canada, cutting an estimated $697K.
- 147 institutional investors held Humacyte (HUMA) as of Q4 2025, up from 141 in Q3 2025.
- Funds reported $53.1M of Humacyte stock for Q4 2025, down 33% quarter-over-quarter.
- 23 funds opened new Humacyte positions in Q4 2025 and 15 closed out, a net change of +8 holders.
- The largest Humacyte buyer in Q4 2025 was Millennium Management, an estimated $2.1M added.
- The largest Humacyte seller in Q4 2025 was Royal Bank of Canada, an estimated $697K sold.
Based on aggregated 13F filings for Q4 2025.